selinexor and Cell-Transformation--Neoplastic

selinexor has been researched along with Cell-Transformation--Neoplastic* in 3 studies

Reviews

1 review(s) available for selinexor and Cell-Transformation--Neoplastic

ArticleYear
Importins and exportins as therapeutic targets in cancer.
    Pharmacology & therapeutics, 2016, Volume: 164

    The nuclear transport proteins, importins and exportins (karyopherin-β proteins), may play an important role in cancer by transporting key mediators of oncogenesis across the nuclear membrane in cancer cells. During nucleocytoplasmic transport of tumor suppressor proteins and cell cycle regulators during the processing of these proteins, aberrant cellular growth signaling and inactivation of apoptosis can occur, both critical to growth and development of tumors. Karyopherin-β proteins bind to these cargo proteins and RanGTP for active transport across the nuclear membrane through the nuclear pore complex. Importins and exportins are overexpressed in multiple tumors including melanoma, pancreatic, breast, colon, gastric, prostate, esophageal, lung cancer, and lymphomas. Furthermore, some of the karyopherin-β proteins such as exportin-1 have been implicated in drug resistance in cancer. Importin and exportin inhibitors are being considered as therapeutic targets against cancer and have shown preclinical anticancer activity. Moreover, synergistic activity has been observed with various chemotherapeutic and targeted agents. However, clinical development of the exportin-1 inhibitor leptomycin B was stopped due to adverse events, including vomiting, anorexia, and dehydration. Selinexor, a selective nuclear export inhibitor, is being tested in multiple clinical trials both as a single agent and in combination with chemotherapy. Selinexor has demonstrated clinical activity in multiple cancers, especially acute myelogenous leukemia and multiple myeloma. The roles of other importin and exportin inhibitors still need to be investigated clinically. Targeting the key mediators of nucleocytoplasmic transport in cancer cells represents a novel strategy in cancer intervention with the potential to significantly affect outcomes.

    Topics: Active Transport, Cell Nucleus; Animals; Cell Nucleus; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Neoplasms; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Triazoles

2016

Other Studies

2 other study(ies) available for selinexor and Cell-Transformation--Neoplastic

ArticleYear
Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors.
    Journal of medicinal chemistry, 2023, 09-14, Volume: 66, Issue:17

    Cancer cells frequently utilize elevated nuclear export to escape tumor suppression and gain proliferative advantage. Chromosome Region Maintenance 1 (CRM1/XPO1) mediates macromolecule nuclear export and plays an important role in tumorigenesis and progression. The clinical approval of its covalent inhibitor KPT-330 (Selinexor) validates the feasibility of targeting CRM1 to treat cancers. Here, we synthesized four aminoratjadone derivatives and found that two of them,

    Topics: Carcinogenesis; Cell Nucleus; Cell Transformation, Neoplastic; Humans; Hydrazines

2023
ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis.
    Cell reports, 2021, 10-19, Volume: 37, Issue:3

    Cell death provides host defense and maintains homeostasis. Zα-containing molecules are essential for these processes. Z-DNA binding protein 1 (ZBP1) activates inflammatory cell death, PANoptosis, whereas adenosine deaminase acting on RNA 1 (ADAR1) serves as an RNA editor to maintain homeostasis. Here, we identify and characterize ADAR1's interaction with ZBP1, defining its role in cell death regulation and tumorigenesis. Combining interferons (IFNs) and nuclear export inhibitors (NEIs) activates ZBP1-dependent PANoptosis. ADAR1 suppresses this PANoptosis by interacting with the Zα2 domain of ZBP1 to limit ZBP1 and RIPK3 interactions. Adar1

    Topics: Adenosine Deaminase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Transformation, Neoplastic; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazines; Interferon-gamma; Male; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Knockout; Necroptosis; Pyroptosis; Receptor-Interacting Protein Serine-Threonine Kinases; RNA-Binding Proteins; Signal Transduction; Skin Neoplasms; Triazoles

2021